Since the 2002 launch of Humira, many products have entered the rheumatoid arthritis (RA) market, but the majority of sales still belongs to the big three anti-TNFs (Enbrel, Humira and Remicade).

Humira is a brand-name drug that’s prescribed for several autoimmune conditions. It contains the active ingredient adalimumab. It isn’t known whether Humira is safe to use during pregnancy or ...

It’s the first time this type of model has been used to bring a Humira biosimilar to market, according to the insurer — and ...

Discover how a long-term battle with rheumatoid arthritis affects daily life, including the impact of infusions and the journey toward independent living.

The last of the three big pharmacy benefit managers has removed Humira from its formulary, starting in the new year. UnitedHealth Group's Optum Rx will take AbbVie's former blockbuster rheumatoid ...

Sept 10 (Reuters) - UnitedHealth Group (UNH.N), opens new tab said on Tuesday it will remove AbbVie’s (ABBV.N), opens new tab blockbuster rheumatoid arthritis drug Humira from some of its lists ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term ...

By Anna Kodé AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end. Businesses had plenty of reasons to ...

You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday ...

Shares of AbbVie (NYSE:ABBV) hit a session low on Tuesday after UnitedHealth (NYSE:UNH) subsidiary Optum announced plans to remove its blockbuster therapy Humira from some of its formulary lists ...

UnitedHealth Group's Optum Rx will join its peers in the big three pharmacy benefit managers by pulling Humira from some of its preferred formularies, according to a report from Reuters.